Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
01/2010
01/28/2010US20100022481 Drug Carriers, Their Synthesis, and Methods of Use Thereof
01/28/2010US20100022480 Solid Oral Dosage Form Containing An Enhancer
01/28/2010US20100022479 Cellular gradient polymer composites
01/28/2010US20100022478 Chiral compounds substituted with phosphonate acid ester functions or phosphonic acid functions
01/28/2010US20100022477 Fused aromatic ptp-1b inhibitors
01/28/2010US20100022476 Pyrazolylamino substituted quinazoles for the treatment of cancer
01/28/2010US20100022474 Polymer Controlled Induced Viscosity Fiber System and Uses Thereof
01/28/2010US20100022473 Use of lipid conjugates in the treatment of diseases associated with vasculature
01/28/2010US20100022472 Liquid, eye-instillable preparations comprising sodium hyaluronate
01/28/2010US20100022471 Oral Moisturizer for Alleviating Dry Mouth
01/28/2010US20100022470 Method for treating allergic diseases
01/28/2010US20100022468 Nucleoside cyclic phosphoramidates for the treatment of rna-dependent rna viral infection
01/28/2010US20100022467 Anti-cancer phosphonate analogs
01/28/2010US20100022466 Thermally-targeted delivery of medicaments including doxorubicin
01/28/2010US20100022465 Method of treating blepharitis
01/28/2010US20100022464 Functional food composition that is rich in phenolic compounds and use of said composition
01/28/2010US20100022463 Feed additive for laying hen and feed containing the same
01/28/2010US20100022462 Appetite suppressant and colon cleansing composition
01/28/2010US20100022461 Novel Derivatives of Cyclic Compound And The Use Thereof
01/28/2010US20100022460 C-phenyl glycitol compound
01/28/2010US20100022458 Methods for treating acute acoustic trauma
01/28/2010US20100022453 NoGo Receptor 1 and Fibroblast Growth Factor Interactions
01/28/2010US20100022449 Receptor-avid exogenous optical contrast and therapeutic agents
01/28/2010US20100022389 Pesticidal Mixtures
01/28/2010US20100021976 Production of polyunsaturated fatty acids, novel biosynthesis genes, and novel plant expression constructs
01/28/2010US20100021574 Pharmaceutical Composition and Procedure to Treat and Prevent Prostatic Hyperplasia and Prostatitis from the Royal Palm (Roystonea regia) Fruits
01/28/2010US20100021571 Compositions and Methods for Treating Acne
01/28/2010US20100021570 Smoking Cessation Treatment By Reducing Nicotine Cravings, Apetite Suppression, And Altering The Perceived Taste Of Tobacco Smoke
01/28/2010US20100021568 Anti-Obesity Product And Its Method Of Preparation
01/28/2010US20100021567 Peganine Isolated from Anisotes Trisulcus L. as a Smoking Deterrent and Anorxigenic Agent
01/28/2010US20100021566 Reverse vitamin k effect via photodynamic oxidation targeted at vascular endothelium, fibrin and blood platelets
01/28/2010US20100021561 Self-preserved aqueous pharmaceutical compositions
01/28/2010US20100021555 Compositions containing high omega-3 and low saturated fatty acid levels
01/28/2010US20100021554 Method for prevention and treatment of reflux injury in the aerodigestive tract and laryngopharynx caused by pepsin
01/28/2010US20100021549 Microparticle oral form useful for the modified release of nanoparticles
01/28/2010US20100021547 Pharmaceutical composition for piperidinoalkanol compounds
01/28/2010US20100021543 Peroral solid pain killer preparation
01/28/2010US20100021542 Extended release oral dosage composition
01/28/2010US20100021541 Microparticulate form of a Tetrahydropyridine derivative
01/28/2010US20100021540 Tablets and Preparation Thereof
01/28/2010US20100021539 Modified Release 1-[(3-Hydroxy-Adamant-1-Ylamino)-Acetyl]-Pyrrolidine-2(S)-Carbonitrile Formulation
01/28/2010US20100021538 Pharmaceutical compositions containing heparin derivatives
01/28/2010US20100021535 Light-stabilized soft capsule formulations
01/28/2010US20100021530 Enhanced trans-keratin drug delivery
01/28/2010US20100021529 Step-down estrogen regimen for women receiving estrogen therapy
01/28/2010US20100021528 Conformable structured therapeutic dressing
01/28/2010US20100021526 Ph modulated films for delivery of actives
01/28/2010US20100021524 Pimethixene derivatives for promoting bone growth
01/28/2010US20100021514 Infection-resistant polyurethane foams, method for producing the same and use thereof in antiseptic wound dressings
01/28/2010US20100021511 Dispersion composition, cosmetic preparation for skin care, and method for producing dispersion composition
01/28/2010US20100021495 Diet product comprising alginate
01/28/2010US20100021493 Extracts of aphanizomenon flos aquae and nutritional, cosmetic and pharmaceutical compositons containing the same
01/28/2010US20100021489 comprising an RNA sequence capable of specifically binding a polypeptide participating in influenza virus infection of cells
01/28/2010US20100021484 Compositions, Methods and Kits Relating to Poxvirus Subunit Vaccines
01/28/2010US20100021482 Novel death associated proteins, and thap1 and par4 pathways in apoptosis control
01/28/2010US20100021475 Methods and compositions for inhibiting the growth of hematopoietic malignant cells
01/28/2010US20100021471 Carbon nanotube-based drug delivery systems and methods of making same
01/28/2010US20100021469 Functional role of adrenomedullin (am) and the gene related product (pamp) in human pathology and physiology
01/28/2010US20100021468 Novel mhc class ii restricted t cell epitopes from the cancer anitgen, ny eso-1
01/28/2010US20100021467 Method of detecting a cancer cell by aberrant expression of a human k+ ion channel
01/28/2010US20100021465 Boris isoforms and methods of detecting and treating disease
01/28/2010US20100021458 Polycyclic agents for the treatment of respiratory syncytial virus infections
01/28/2010US20100021448 I-crei meganuclease variants with modified specificity, method of preparation and uses thereof
01/28/2010US20100021432 Sensitization of Chemotherapeutic Agent Resistant Neoplastic Cells with a Virus
01/28/2010US20100021425 1'-substituted carba-nucleoside analogs for antiviral treatment
01/28/2010US20100021423 Heterocyclic antiviral compounds
01/28/2010US20100021421 Fusion proteins and methods for modulation of immune response
01/28/2010US20100021420 Combinations of pyrazole derivatives for the inhibition of cdks and gsk's
01/28/2010US20100021416 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
01/28/2010US20100021415 Cosmetic use of organic resinates
01/28/2010US20100021405 External preparation for skin
01/28/2010US20100021402 Compounds, Formulations, and Methods for Ameliorating Telangiectasis
01/28/2010US20100021399 Cosmetic or dermatological preparations comprising n-acetylcysteine
01/28/2010US20100021395 Crystalline forms of a biphenyl compound
01/28/2010US20100021394 High penetration prodrug compositions of 1h-imidazo[4,5-c]quinolin-4-amines and 1h-imidazo[4,5-c]quinolin-4-amine-related compounds
01/28/2010US20100021388 Benzothiazole derivative compounds, compositions and uses
01/28/2010US20100021387 Methods for Inducing Reversible Stasis
01/28/2010US20100021386 Treatment, prevention,and reversal of alcohol-induced liver disease
01/28/2010US20100021385 Benzoxazole derivatives
01/28/2010US20100021380 Dieghylenetriaminepentaacetic acid (dtpa)-modified ferrofluid, preparation method of the same and uses of the same in preparation of peptide ferrofluid
01/28/2010US20100018523 Composition, device, and method for treating sexual dysfunction via inhalation
01/28/2010DE10297018B4 Depotmikrokügelchen für die Injektion von Huperzin-A-Verbindungen Depot microspheres for injection of Huperzine A compounds
01/28/2010DE102008035442A1 Zubereitungen aus Artemisia Annua, ihre Umwandlung in Mikro- und Nanopartikel und ihre Verwendung Preparations from Artemisia annua, their conversion into micro- and nanoparticles and their use
01/28/2010DE102008034741A1 Zubereitung zur Schutzimpfung von Equiden, insbesondere Pferden, gegen Hufrehe Preparation for the vaccination of equidae, in particular horses, against laminitis
01/28/2010DE102008034739A1 Preparation, useful for the treatment of equine Cushing's syndrome, comprises allopurinol
01/28/2010DE102008034265A1 Wirkstoffkombination aus Anisfruchtextrakt und Hyaluronsäure Active ingredient combination of anise fruit and hyaluronic acid
01/28/2010CA2767560A1 Atovaquone with a particle size diameter range (d90) of greater than 3um to about 10um
01/28/2010CA2734991A1 Activation of histone deacetylase 1 (hdac1) protects against dna damage and increases neuronal survival
01/28/2010CA2732229A1 Enhancement of sirna silencing activity using universal bases or mismatches in the sense strand
01/28/2010CA2732228A1 Methods and compositions for treating and preventing autoimmune diseases
01/28/2010CA2731938A1 Solid pharmaceutical composition comprising exemestane
01/28/2010CA2731869A1 Beta-and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
01/28/2010CA2731849A1 Treating various disorders with 7,8-dihydroxyflavone and derivatives thereof
01/28/2010CA2731789A1 Alkyl thiazole carbamate derivatives, preparation thereof, and use thereof as faah enzyme inhibitors
01/28/2010CA2731779A1 Rnai constructs and uses therof
01/28/2010CA2731773A1 Amidophenoxyindazoles useful as inhibitors of c-met
01/28/2010CA2731769A1 Controlled-release otic structure modulating and innate immune system modulating compositions and methods for the treatment of otic disorders
01/28/2010CA2731730A1 Deacetylase inhibitors and uses thereof
01/28/2010CA2731650A1 Monocyclic cyanoenones and methods of use thereof
01/28/2010CA2731634A1 Estratriene derivatives comprising heterocyclic bioisosteres for the phenolic a-ring